The first biosimilar version of Pfizer/Amgen’s multi-billion-dollar anti-inflammatory Enbrel (etancerpt) has now been launched in the UK, offering access to a cheaper alternative that could drive down ...

The joint venture between Biogen (NASDAQ: BIIB) and Samsung BioLogics, Samsung Bioepis, has been granted European Commission (EC) approval for BENEPALI ®, an etanercept biosimilar referencing Enbrel ® ...

ZUG, Switzerland--(BUSINESS WIRE)--The joint venture between Biogen (NASDAQ:BIIB) and Samsung BioLogics, Samsung Bioepis, has been granted European Commission (EC) approval for BENEPALI® , an ...

Shares of Biogen Inc (NASDAQ: BIIB) were trading higher by 2 percent at $279.00 early Tuesday morning after the company announced that the European Union has granted marketing authorization for its ...

LIVERPOOL -- Switching from etanercept (Enbrel) to its biosimilar Benepali was successfully implemented in a single-center study of patients with rheumatoid arthritis, investigators reported here.

The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use has recommended approval of Benepali, a biosimilar of etanercept (Enbrel, Immunex and Amgen), for treatment of ...

Norway became the first overseas country to approve the Enbrel biosimilar made by Samsung Bioepis for sale, coming two weeks after the drug, Benepali, was approved by ...

ZUG, Switzerland--(BUSINESS WIRE)--Real world evidence from investigator-initiated studies supported by Biogen (NASDAQ: BIIB), demonstrating sustained efficacy and safety, and high acceptance and ...

Octopus Energy Generation said on Wednesday it had invested 584 million euros ($630 million) to acquire a portfolio ‌of onshore wind farms across France, Germany and Poland, as part of a push to ...

“Since BENEPALI and FLIXABI launched more than two years ago, they have played an increasingly important role in widening access to life-enhancing treatment options for patients and healthcare systems ...

BENEPALI, as the first etanercept biosimilar referencing Enbrel approved in the EU, can help expand access to treatment options for people affected by chronic inflammatory conditions.” The EC approval ...